ATE203025T1 - Reverse-turnmimetika und damit zusammenhängendes verfahren - Google Patents

Reverse-turnmimetika und damit zusammenhängendes verfahren

Info

Publication number
ATE203025T1
ATE203025T1 AT96937733T AT96937733T ATE203025T1 AT E203025 T1 ATE203025 T1 AT E203025T1 AT 96937733 T AT96937733 T AT 96937733T AT 96937733 T AT96937733 T AT 96937733T AT E203025 T1 ATE203025 T1 AT E203025T1
Authority
AT
Austria
Prior art keywords
reverse
turn mimetics
related method
reverse turn
disclosed
Prior art date
Application number
AT96937733T
Other languages
English (en)
Inventor
Michael Kahn
Original Assignee
Molecumetics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecumetics Ltd filed Critical Molecumetics Ltd
Application granted granted Critical
Publication of ATE203025T1 publication Critical patent/ATE203025T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
  • Toys (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT96937733T 1995-10-27 1996-10-24 Reverse-turnmimetika und damit zusammenhängendes verfahren ATE203025T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/549,007 US5929237A (en) 1995-10-27 1995-10-27 Reverse-turn mimetics and methods relating thereto
PCT/US1996/017053 WO1997015577A1 (en) 1995-10-27 1996-10-24 Reverse-turn mimetics and methods relating thereto

Publications (1)

Publication Number Publication Date
ATE203025T1 true ATE203025T1 (de) 2001-07-15

Family

ID=24191284

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96937733T ATE203025T1 (de) 1995-10-27 1996-10-24 Reverse-turnmimetika und damit zusammenhängendes verfahren

Country Status (10)

Country Link
US (1) US5929237A (de)
EP (1) EP0876371B1 (de)
JP (1) JPH11513986A (de)
KR (1) KR19990067102A (de)
AT (1) ATE203025T1 (de)
AU (1) AU719620B2 (de)
CA (1) CA2235138C (de)
DE (1) DE69613861T2 (de)
ES (1) ES2158360T3 (de)
WO (1) WO1997015577A1 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184223B1 (en) 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
EP1015028A2 (de) * 1997-09-19 2000-07-05 Serex, Inc. Verfahren zur verbesserung der immunogenizität von antigenen und der spezifizität von antikörpern
AU767185B2 (en) 1998-03-23 2003-11-06 President And Fellows Of Harvard College Synthesis of compounds and libraries of compounds
AUPP254898A0 (en) * 1998-03-24 1998-04-23 University Of Queensland, The Peptide turn mimetics
US6294525B1 (en) 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
PE20010955A1 (es) * 1999-12-21 2001-10-11 Procter & Gamble Compuestos mimeticos de peptidos de giros beta y procesos para su fabricacion
US6872825B2 (en) 1999-12-21 2005-03-29 The Procter & Gamble Company Peptide β-turn mimetic compounds and processes for making them
AU2002250293B2 (en) * 2001-03-09 2007-10-11 Arnason, Barry G. Mr Polymeric immunoglobulin fusion proteins that target low-affinity FCGammaReceptors
US8163289B2 (en) * 2001-03-09 2012-04-24 Iterative Therapeutics, Inc. Methods and compositions involving polymeric immunoglobulin fusion proteins
US7662960B2 (en) * 2001-04-26 2010-02-16 Choongwae Pharma Corporation Beta-strand mimetics and method relating thereto
WO2002092010A2 (en) * 2001-05-16 2002-11-21 Molecumetics, Ltd. Reverse-turn mimetics and methods relating thereto
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
WO2003030907A1 (en) * 2001-10-09 2003-04-17 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
EP1444235B1 (de) * 2001-10-12 2008-06-11 Choongwae Pharma Corporation Reverse-turn-mimetika und diese betreffendes verfahren
US7576084B2 (en) * 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7671054B1 (en) * 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US8080657B2 (en) * 2001-10-12 2011-12-20 Choongwae Pharma Corporation Compounds of reverse turn mimetics and the use thereof
US20040072831A1 (en) * 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7232822B2 (en) * 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7041499B2 (en) 2001-12-12 2006-05-09 University Of North Texas Health Science Center Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
US6762185B1 (en) 2002-03-01 2004-07-13 Choongwae Pharma Corporation Compounds useful for treatment of cancer, compositions containing the same, and methods of their use
AU2003284120A1 (en) * 2002-10-17 2004-05-04 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
CA2537099A1 (en) 2003-08-28 2005-03-10 Choongwae Pharma Corporation Modulation of .beta.-catenin/tcf activated transcription
US20050222158A1 (en) * 2004-03-19 2005-10-06 Andres Charles J Jr Method of treating migraine headaches using calcitonin gene related peptide mimetics
US20050209256A1 (en) * 2004-03-19 2005-09-22 Andres Charles J Jr Novel beta-turn mimetics as calcitonin gene related peptide receptor antagonists
US7915251B2 (en) 2005-03-18 2011-03-29 Institute For Chemical Genomics Alpha-helix mimetics and methods relating to the treatment of fibrosis
WO2007056593A2 (en) * 2005-11-08 2007-05-18 Choongwae Pharma Corporation α-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS
EP1991577A2 (de) 2006-01-31 2008-11-19 Parkinson, John F. Modulation der mdl-1-aktivität zur behandlung entzündlicher krankheiten
US7964181B2 (en) * 2006-03-30 2011-06-21 Palatin Technologies, Inc. Amino acid surrogates for peptidic constructs
US8580746B2 (en) * 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
US8114844B2 (en) * 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
US20100055113A1 (en) 2006-07-27 2010-03-04 The University Of Maryland, Baltimore Cellular receptor for antiproliferative factor
EP2155226A4 (de) * 2007-06-14 2010-07-28 Univ California Verbindungen zur hemmung der proteinaggregation und verfahren zu deren herstellung und verwendung
JP2009040696A (ja) * 2007-08-07 2009-02-26 Kikkoman Corp 新規アンジオテンシン変換酵素阻害ペプチド
BRPI0906429B1 (pt) 2008-01-10 2021-08-03 Research Development Foundation Método de identificação de uma infecção por e. chaffeensis em um indivíduo, uso de um ou mais polipeptídeo sintético e kit
US8343958B2 (en) 2008-02-29 2013-01-01 Mimetica Pty Ltd 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5-receptor antagonists
US8008291B2 (en) 2008-02-29 2011-08-30 Mimetica Pty Ltd 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
US8377925B2 (en) 2008-02-29 2013-02-19 Mimetica Pty Ltd Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor
JP5530427B2 (ja) 2008-06-06 2014-06-25 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ アルファへリックスミメティック及び関連の方法
US20110237524A1 (en) * 2008-09-19 2011-09-29 Nektar Therapeutics Polymer conjugates of aod-like peptides
US20110171165A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of opioid growth factor peptides
US20110171164A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
EP2344200A2 (de) * 2008-09-19 2011-07-20 Nektar Therapeutics Modifizierte therapeutische peptide, herstellungsverfahren und verwendung
EP2340047A1 (de) * 2008-09-19 2011-07-06 Nektar Therapeutics Polymerkonjugate von kiss1-peptiden
WO2010033204A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of c-peptides
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
US20110171166A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of osteocalcin peptides
WO2010033227A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of thymosin alpha 1 peptides
EP2334335A1 (de) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymerkonjugate von cd-np-peptiden
CN102186853A (zh) 2008-10-14 2011-09-14 株式会社棱镜生物实验室 治疗癌症α-螺旋模拟物
US8524669B2 (en) 2008-10-17 2013-09-03 Dana-Farber Cancer Institute, Inc. MUC-1 cytoplasmic domain peptides as inhibitors of cancer
CA2758904C (en) * 2009-04-15 2017-04-04 Jw Pharmaceutical Corporation Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof
ES2568938T3 (es) 2009-04-28 2016-05-05 Vanderbilt University Composiciones y procedimientos de tratamiento de trastornos que implican apoptosis de células epiteliales
EP2427451B1 (de) 2009-05-07 2019-03-20 PRISM BioLab Co., Ltd. Alpha-helix-mimetika und damit in zusammenhang stehende methoden
WO2011096440A1 (ja) 2010-02-03 2011-08-11 ＰＲＩＳＭ ＢｉｏＬａｂ株式会社 天然変性タンパク質に結合する化合物およびそのスクリーニング方法
US8952054B2 (en) 2010-03-15 2015-02-10 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of MUC1 and methods of identifying the same
ES2552462T3 (es) 2010-10-14 2015-11-30 Jw Pharmaceutical Corporation Nuevo compuesto de un mimético de giro inverso y un procedimiento de producción y uso del mismo
WO2012115286A1 (en) 2011-02-25 2012-08-30 Prism Biolab Corporation Alpha helix mimetics and methods relating thereto
US9140698B2 (en) 2011-04-06 2015-09-22 The Board Of Regents Of The University Of Texas System Modulating bacterial MAM polypeptides in pathogenic disease
WO2013018097A2 (en) 2011-08-01 2013-02-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Novel sequences for the control of reproduction in fish
WO2013026015A1 (en) 2011-08-18 2013-02-21 Dana-Farber Cancer Institute, Inc. Muc1 ligand traps for use in treating cancers
WO2014045126A2 (en) 2012-09-18 2014-03-27 Uti Limited Partnership Treatment of pain by inhibition of usp5 de-ubiquitinase
WO2014164395A1 (en) 2013-03-11 2014-10-09 Dana-Farber Cancer Institute, Inc. Combination anti-estrogen receptor cancer therapy using muc1 peptides and chemotherapeutics
US9789156B2 (en) 2013-03-11 2017-10-17 Dana-Farber Cancer Institute, Inc. Combination anti-human epidermal growth factor receptor 2 (anti-HER2) cancer therapy using mucin 1 (MUC1) peptides and hemotherapeutics
BR112015021866A2 (pt) 2013-03-15 2017-08-29 Bayer Healthcare Llc Domínios de gla como agentes direcionadores
CN105899211A (zh) 2013-10-18 2016-08-24 小路弘行 使用cbp/连环蛋白的抑制剂治疗肝纤维化
WO2018035429A1 (en) 2016-08-18 2018-02-22 Wisconsin Alumni Research Foundation Peptides that inhibit syndecan-1 activation of vla-4 and igf-1r
EP3679129A1 (de) 2017-09-05 2020-07-15 GLAdiator Biosciences, Inc. Verfahren zur intrazellulären abgabe
CN117083065A (zh) 2020-10-30 2023-11-17 庆应义塾 肌肉减少症相关疾病等的新颖治疗和预防
EP4436595A1 (de) 2021-11-22 2024-10-02 Pfizer Inc. Verringerung des risikos von antigen-mimetika in immunogenen arzneimitteln

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013878A2 (en) * 1991-02-07 1992-08-20 Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
CA2141447A1 (en) * 1992-08-06 1994-02-17 Michael Kahn Conformationally restricted mimetics of reverse turns and peptides containing the same
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5886186A (en) * 1995-10-25 1999-03-23 Versicor, Inc. Synthesis of substituted N-heteroaromatic compounds and methods of use thereof

Also Published As

Publication number Publication date
JPH11513986A (ja) 1999-11-30
AU7520596A (en) 1997-05-15
WO1997015577A1 (en) 1997-05-01
KR19990067102A (ko) 1999-08-16
AU719620B2 (en) 2000-05-11
DE69613861T2 (de) 2001-11-15
EP0876371A1 (de) 1998-11-11
CA2235138C (en) 2005-04-05
DE69613861D1 (de) 2001-08-16
EP0876371B1 (de) 2001-07-11
US5929237A (en) 1999-07-27
CA2235138A1 (en) 1997-05-01
ES2158360T3 (es) 2001-09-01

Similar Documents

Publication Publication Date Title
ATE203025T1 (de) Reverse-turnmimetika und damit zusammenhängendes verfahren
CA2286733A1 (en) Reverse-turn mimetics and methods relating thereto
ATE301656T1 (de) Reverse-turnmimetika und damit zusammenhängendes verfahren
DE60227093D1 (de) Reverse-turn-mimetika und diese betreffendes verfahren
BRPI0409124A (pt) miméticos de direção inversa e método relacionado aos mesmos
BRPI0509888A (pt) miméticos de direção inversa e método relacionado aos mesmos
EP0772590A4 (de) Thrombin-inhibitoren
EP0820287A4 (de) Thrombininhibitoren
DK0600866T3 (da) Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
PT735818E (pt) Proteinas inflamatorias de macrofagos pim-3 pim-4 e pim-1y
EE200000318A (et) Uudsed ühendid
ATE221531T1 (de) Kristallmodifikation des cdch, verfahren zu dessen herstellung und diese enthaltende pharmazeutische zubereitungen
YU34196A (sh) Peptidi i jedinjenja koja se vezuju za receptor
DE69624406D1 (de) Verfahren zur Analyse von biologisch aktiven Substanzen
DE59608154D1 (de) Verwendung von polyasparaginsäureamiden als lederhilfsmittel
FI973254L (fi) Menetelmä aminoetyylietanoliamiinin ja/tai hydroksietyylipiperatsiinin valmistamiseksi
NO981864L (no) Oppl°sningsmetoder
WO2002092010A3 (en) Reverse-turn mimetics and methods relating thereto
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
DK403384D0 (da) Enteralt effektivt, biologisk aktivt peptid- eller proteinmiddel ogfremgangsmaader til fremstilling deraf
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
PT1107981E (pt) Sintese de analogos peptidicos ciclicos de anel modificado
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
BRPI0318325B8 (pt) compostos miméticos de beta-fita

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties